Florent Delhommel

Florent Delhommel

Auto-generated profile, based on publicly available information

Florent Delhommel

Bavarian NMR Center & Department of Bioscience, TUM School of Natural Sciences, Technical University of Munich (TUM), 85748 Garching, Germany; Institute of Structural Biology, Molecular Targets and Therapeutics Center, Helmholtz Munich, 85764 Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TTTania Tahtouh
Tania Tahtouh
JEJonathan M. Elkins
Jonathan M. Elkins
PFPanagis Filippakopoulos
Panagis Filippakopoulos
MSMeera Soundararajan
Meera Soundararajan
GBGuillaume Burgy
Guillaume Burgy
LMLaurent Meijer
Laurent Meijer

17 December 2021 in Science Advances
Verified
Journal Article
Open access
ALAbraham Lopez
Abraham Lopez
VDVinay Dahiya
Vinay Dahiya
FDFlorent Delhommel
Florent Delhommel
LFLee Freiburger
Lee Freiburger
RSRalf Stehle
Ralf Stehle
MSMichael Sattler
Michael Sattler
ATP-driven conformational selection of Hsp90 conformations modulates the binding of clients and co-chaperones.

18 June 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
SKSusanna Kinting
Susanna Kinting
YLYang Li
Yang Li
MFMaria Forstner
Maria Forstner
FDFlorent Delhommel
Florent Delhommel
MSMichael Sattler
Michael Sattler
MGMatthias Griese
Matthias Griese
ABCA3 is a phospholipid transporter implicated in pulmonary surfactant homoeostasis and localized at the limiting membrane of lamellar bodies, the storage compartment for surfactant in alveolar type II cells. Mutations in ABCA3 display a common genetic cause for diseases caused by surfactant deficiency like respiratory distress in neonates and interstitial lung disease in children and adults, for which currently no causal therapy exists. In this study, we investigated the effects of ivacaftor and genistein, two potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR), on ABCA3‐specific lipid transport function. Wild‐type (WT) and functional ABCA3 mutations N568D, F629L, G667R, T1114M and L1580P were stably expressed in A549 cells. Three‐dimensional modelling predicted functional impairment for all five mutants that was confirmed by in vitro experiments (all <14% of WT functional activity). Treatment with potentiators rescued the mutants N568D (up to 114% of WT), F629L (up to 47% of WT), and G667R (up to 60% of WT), the latter variation needing higher concentrations of genistein, showing reduced affinity of the potentiator to the mutant protein. Our results present a first proof that functional ABCA3 mutations are rescued by CFTR potentiators, making them a potential therapeutical option for patients suffering from surfactant deficiency due to ABCA3 mutations.

1 October 2015 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
CCCélia Caillet-Saguy
Célia Caillet-Saguy
PMPierre Maisonneuve
Pierre Maisonneuve
FDFlorent Delhommel
Florent Delhommel
ETElouan Terrien
Elouan Terrien
NBNicolas Babault
Nicolas Babault
NWNicolas Wolff
Nicolas Wolff

17 February 2021 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
LSLuise A. Schuch
Luise A. Schuch
MFMaria Forstner
Maria Forstner
CRChristina Katharina Rapp
Christina Katharina Rapp
YLYang Li
Yang Li
DSDesiree E. C. Smith
Desiree E. C. Smith
MGMatthias Griese
Matthias Griese
Aminoacyl‐tRNA synthetases (ARSs) catalyze the first step of protein biosynthesis (canonical function) and have additional (non‐canonical) functions outside of translation. Bi‐allelic pathogenic variants in genes encoding ARSs are associated with various recessive mitochondrial and multisystem disorders. We describe here a multisystem clinical phenotype based on bi‐allelic mutations in the two genes (FARSA, FARSB) encoding distinct subunits for tetrameric cytosolic phenylalanyl‐tRNA synthetase (FARS1). Interstitial lung disease with cholesterol pneumonitis on histology emerged as an early characteristic feature and significantly determined disease burden. Additional clinical characteristics of the patients included neurological findings, liver dysfunction, and connective tissue, muscular and vascular abnormalities. Structural modeling of newly identified missense mutations in the alpha subunit of FARS1, FARSA, showed exclusive mapping to the enzyme's conserved catalytic domain. Patient‐derived mutant cells displayed compromised aminoacylation activity in two cases, while remaining unaffected in another. Collectively, these findings expand current knowledge about the human ARS disease spectrum and support a loss of canonical and non‐canonical function in FARS1‐associated recessive disease.

1 November 2017 in Structure
Verified
Journal Article
Closed access
FDFlorent Delhommel
Florent Delhommel
FCFlorence Cordier
Florence Cordier
BBBenjamin Bardiaux
Benjamin Bardiaux
GBGuillaume Bouvier
Guillaume Bouvier
BCBaptiste Colcombet-Cazenave
Baptiste Colcombet-Cazenave
NWNicolas Wolff
Nicolas Wolff